Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Return on Equity (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Return on Equity for 4 consecutive years, with 0.43% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 62.0% to 0.43% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.43% through Dec 2025, up 62.0% year-over-year, with the annual reading at 0.64% for FY2025, 52.0% up from the prior year.
  • Return on Equity hit 0.43% in Q4 2025 for Taysha Gene Therapies, down from 0.4% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 19.04% in Q1 2023 to a low of 28.38% in Q4 2022.
  • Historically, Return on Equity has averaged 1.11% across 4 years, with a median of 0.82% in 2024.
  • Biggest five-year swings in Return on Equity: skyrocketed 2266bps in 2023 and later crashed -2027bps in 2024.
  • Year by year, Return on Equity stood at 28.38% in 2022, then soared by 80bps to 5.72% in 2023, then surged by 82bps to 1.06% in 2024, then skyrocketed by 59bps to 0.43% in 2025.
  • Business Quant data shows Return on Equity for TSHA at 0.43% in Q4 2025, 0.4% in Q3 2025, and 0.57% in Q2 2025.